
Sign up to save your podcasts
Or
On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
5
77 ratings
On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more.
Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).
38,139 Listeners
27,310 Listeners
30,965 Listeners
22,099 Listeners
43,482 Listeners
3,453 Listeners
2,606 Listeners
9,366 Listeners
8,222 Listeners
57,779 Listeners
4,347 Listeners
2,039 Listeners
9,564 Listeners
14 Listeners
5,093 Listeners